Videos

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

The director of the Healey & AMG Center for ALS spoke to the recent topline results of a phase 3 study of NurOwn in patients with the neuromuscular disease.

Chimeric antigen receptor (CAR) T-cell exhaustion likely stems from chemotherapy prior to transplant, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses how stem cell therapy and heart health can help patients manage beta thalassemia.

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109​, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses ​the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.

Matthew J. Frigault, MD, reviews the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma and real-world data supporting it's use.

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.